← back to search

Lixia Jiao

Berry Oncology (China) · CN
Area of research
Nutrition and Dietetics · Surgery
Research interest
Research interests include Fatty Acid Research and Health, Lipoproteins and Cardiovascular Health, Diet and metabolism studies, and Eicosanoids and Hypertension Pharmacology.
h-index
17
citations
5,218
works
41
NIH funding
primary concept
Medicine
email

Recent publications

Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial
European Heart Journal 2024cited by 27position: middledoi
Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE‐IT
Journal of the American Heart Association 2023cited by 25position: middledoi
Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy
Circulation 2022cited by 124position: middledoi
Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction
Journal of the American College of Cardiology 2022cited by 57position: middledoi
Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking
European Heart Journal - Cardiovascular Pharmacotherapy 2022cited by 17position: middledoi
Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT
Journal of the American College of Cardiology 2021cited by 34position: middledoi
Reduction in Revascularization With Icosapent Ethyl
Circulation 2020cited by 57position: middledoi
REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results
European Heart Journal - Cardiovascular Pharmacotherapy 2020cited by 26position: middledoi
Effects of Icosapent Ethyl on Total Ischemic Events
Journal of the American College of Cardiology 2019cited by 256position: middledoi
REDUCE-IT USA
Circulation 2019cited by 133position: middledoi
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
New England Journal of Medicine 2018cited by 3,206position: middledoi
Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis
JAMA 2016cited by 782position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Terry A. Jacobson · Emory University11 papers (2018–2024)Philippe Gabríel Steg · Mount Sinai Hospital11 papers (2018–2024)Deepak L. Bhatt · Technische Universität Dresden11 papers (2018–2024)Eliot A. Brinton · Icahn School of Medicine at Mount Sinai11 papers (2018–2024)Christie M. Ballantyne · New York University11 papers (2018–2024)Michael Miller · University of Colorado Anschutz Medical Campus10 papers (2018–2024)Jean‐Claude Tardif · United States Nuclear Regulatory Commission10 papers (2018–2024) · 9 papers (2018–2024)Steven Ketchum · Mount Sinai Hospital8 papers (2018–2024)Rebecca A. Juliano · Rapt Therapeutics (United States)8 papers (2018–2023)Craig Granowitz · Opexa Therapeutics (United States)7 papers (2018–2022)Matthew J. Budoff · Phoenix (United States)4 papers (2019–2022)C. Michael Gibson · CytoSorbents (United States)4 papers (2019–2022)Robert P. Giugliano · Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo4 papers (2019–2022)Mina K. Chung · Broad Institute3 papers (2019–2023)Brian Olshansky · Covenant Medical Center3 papers (2019–2023)Duane S. Pinto · University of Birmingham2 papers (2020–2021)R. Preston Mason · Harvard University2 papers (2022–2022)Prakriti Gaba · Harvard University2 papers (2021–2022)Claus Bachert · Sun Yat-sen University1 papers (2016–2016)